Relapsing Forms of Multiple Sclerosis Completed Phase 0 Trials for Natalizumab (DB00108)

IndicationStatusPhase
DBCOND0036449 (Relapsing Forms of Multiple Sclerosis)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00424788A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)Treatment